OpenURL Connection Search

Select item for more details and to access through your institution.

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.
Published in:
European Journal of Neurology, 2005, v. 12, n. 11, p. 869, doi. 10.1111/j.1468-1331.2005.01084.x
By:
- Weder, C.;
- Baltariu, G. M.;
- Wyler, K. A.;
- Gober, H.-J.;
- Lienert, C.;
- Schluep, M.;
- Radü, E. W.;
- de Libero, G.;
- Kappos, L.;
- Duda, P. W.
Publication type:
Article
Keynote Speakers.
Published in:
Multiple Sclerosis (13524585), 2001, v. 7, p. S1, doi. 10.1177/1352458501007001011
By:
- Hobart, J. C.;
- Vickrey, B. G.;
- Riise, T.;
- Nortvedt, M. W.;
- Young, C. A.;
- Robertson, I. H.;
- Matthews, P. M.;
- Kappos, L.;
- Leppert, D.;
- Lienert, C.;
- Ebers, George;
- Feinstein, A.;
- Fowler, Clare J.;
- Miller, D. M.;
- Blalcemore, W. F.;
- Miller, David;
- Lucchinetti, C. F.;
- Bruck, W.;
- Lassmann, H.;
- Thompson, A. J.
Publication type:
Article
Use of composite scores in the quantification of deterioration in multiple sclerosis.
Published in:
Multiple Sclerosis (13524585), 1999, v. 5, n. 4, p. 220, doi. 10.1191/135245899678846122
By:
- Lienert, C.;
- Lechner-Scott, J.;
- Schött, D.;
- Constantinescu, C.;
- Kappos, L.
Publication type:
Article
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Published in:
Multiple Sclerosis Journal, 2016, v. 22, n. 4, p. 533, doi. 10.1177/1352458515594440
By:
- Kuhle, J.;
- Hardmeier, M.;
- Disanto, G.;
- Gugleta, K.;
- Ecsedi, M.;
- Lienert, C.;
- Amato, M. P.;
- Baum, K.;
- Buttmann, M.;
- Bayas, A.;
- Brassat, D.;
- Brochet, B.;
- Confavreux, C.;
- Edan, G.;
- Färkkilä, M.;
- Fredrikson, S.;
- Frontoni, M.;
- D’Hooghe, M.;
- Hutchinson, M.;
- De Keyser, J.
Publication type:
Article
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.
Published in:
Brain: A Journal of Neurology, 1998, v. 121, n. 12, p. 2327, doi. 10.1093/brain/121.12.2327
By:
- Leppert, D;
- Ford, J;
- Stabler, G;
- Grygar, C;
- Lienert, C;
- Huber, S;
- Miller, KM;
- Hauser, SL;
- Kappos, L
Publication type:
Article
Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.
Published in:
European Journal of Neurology, 2020, v. 27, n. 6, p. 1066, doi. 10.1111/ene.14191
By:
- Wyl, V.;
- Décard, B. F.;
- Benkert, P.;
- Lorscheider, J.;
- Hänni, P.;
- Lienert, C.;
- Kuhle, J.;
- Derfuss, T.;
- Kappos, L.;
- Yaldizli, Ö.
Publication type:
Article

Found: 6

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.

Keynote Speakers.

Use of composite scores in the quantification of deterioration in multiple sclerosis.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.